Popular weight loss drugs have been linked to gastrointestinal, mental health, and vision problems, but the benefits appear ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

Glucagon-like peptide-1 receptor (GLP-1) agonists, particularly semaglutide, could be effective in reducing alcohol-related hospitalisations. Read more!

As optimism for GLP-1 receptor agonists for weight loss has grown, so too has their use in children. Currently, liraglutide ...

Coya Therapeutics (COYA) releases the following letter to stockholders from Chief Executive Officer Dr. Arun Swaminathan….”Given my recent ...

In recent years, GLP-1 agonist medications like Ozempic have gained notoriety for their weight loss effects and blood sugar regulation. However, these pharmaceuticals come with a host of potential ...

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...

A long-term study suggests GLP-1 agonists, especially semaglutide, may lower the risk of alcohol use disorder hospitalizations, highlighting the potential for novel treatments pending further ...

In part 1 of the so-called ESSENCE trial, treatment with the GLP-1 receptor agonist resulted in higher week-72 rates of steatohepatitis resolution without worsening of liver fibrosis (63% vs 34% ...

Dr, Garner said, "Glucagon-like peptide-1 (GLP-1) receptor agonists represent a significant advancement in the treatment of ...